Ventas, Inc.

NYSE:VTR Stock Report

Market Cap: US$46.5b

Ventas Valuation

Is VTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: VTR ($89.99) is trading below our estimate of future cash flow value ($119)

Significantly Below Future Cash Flow Value: VTR is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTR?

Key metric: As VTR is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VTR. This is calculated by dividing VTR's market cap by their current revenue.
What is VTR's PS Ratio?
PS Ratio7.2x
SalesUS$6.42b
Market CapUS$46.47b

Price to Sales Ratio vs Peers

How does VTR's PS Ratio compare to its peers?

The above table shows the PS ratio for VTR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.6x
OHI Omega Healthcare Investors
11.3x-0.56%US$14.9b
DOC Healthpeak Properties
4.7x6.05%US$14.3b
AHR American Healthcare REIT
4.9x16.01%US$12.5b
WELL Welltower
13.3x13.63%US$169.8b
VTR Ventas
7.2x10.58%US$46.5b

Price-To-Sales vs Peers: VTR is good value based on its Price-To-Sales Ratio (7.2x) compared to the peer average (8.6x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does VTR's PS Ratio compare vs other companies in the US Health Care REITs Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
GBCS Selectis Health
0.5xn/aUS$16.72m
No more companies available in this PS range
VTR 7.2xIndustry Avg. 6.5xNo. of Companies3PS03.26.49.612.816+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VTR is expensive based on its Price-To-Sales Ratio (7.2x) compared to the Global Health Care REITs industry average (6.5x).

Price to Sales Ratio vs Fair Ratio

What is VTR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.2x
Fair PS Ratio5.8x

Price-To-Sales vs Fair Ratio: VTR is expensive based on its Price-To-Sales Ratio (7.2x) compared to the estimated Fair Price-To-Sales Ratio (5.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VTR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$89.99
US$101.86
+13.19%
5.94%US$113.00US$90.00n/a22
Sep ’27US$92.07
US$101.77
+10.54%
6.06%US$113.00US$90.00n/a22
Aug ’27US$93.51
US$99.68
+6.60%
6.79%US$114.00US$86.00n/a22
Jul ’27US$89.65
US$96.62
+7.77%
5.96%US$110.00US$86.00n/a21
Jun ’27US$81.71
US$96.80
+18.47%
5.71%US$110.00US$86.00n/a20
May ’27US$88.02
US$94.20
+7.02%
4.52%US$102.00US$85.00n/a20
Apr ’27US$82.01
US$92.75
+13.10%
4.70%US$102.00US$85.00n/a20
Mar ’27US$86.16
US$90.15
+4.63%
5.31%US$100.00US$81.00n/a20
Feb ’27US$77.67
US$86.50
+11.37%
5.34%US$94.00US$80.00n/a20
Jan ’27US$77.38
US$85.15
+10.04%
5.79%US$93.00US$75.00n/a20
Dec ’26US$80.39
US$83.35
+3.68%
6.57%US$91.00US$70.00n/a20
Nov ’26US$73.79
US$78.25
+6.04%
5.08%US$85.00US$70.00n/a20
Oct ’26US$70.32
US$77.30
+9.93%
4.21%US$84.00US$70.00n/a20
Sep ’26US$68.08
US$77.39
+13.67%
4.16%US$84.00US$70.00US$92.0718
Aug ’26US$67.50
US$75.89
+12.43%
5.55%US$84.00US$69.00US$93.5118
Jul ’26US$62.87
US$75.84
+20.63%
5.30%US$83.00US$69.00US$89.6519
Jun ’26US$64.28
US$75.95
+18.15%
5.45%US$83.00US$69.00US$81.7119
May ’26US$65.54
US$75.89
+15.80%
5.67%US$84.00US$68.00US$88.0219
Apr ’26US$69.27
US$75.42
+8.88%
7.66%US$93.00US$65.00US$82.0119
Mar ’26US$69.18
US$73.68
+6.51%
8.68%US$93.00US$65.00US$86.1619
Feb ’26US$60.42
US$71.26
+17.95%
5.67%US$81.00US$65.00US$77.6719
Jan ’26US$58.89
US$71.58
+21.55%
5.65%US$81.00US$65.00US$77.3819
Dec ’25US$64.07
US$70.37
+9.83%
7.01%US$79.00US$55.00US$80.3919
Nov ’25US$64.19
US$67.74
+5.53%
7.59%US$76.00US$55.00US$73.7919
Oct ’25US$63.89
US$65.26
+2.15%
8.78%US$73.00US$55.00US$70.3219
Sep ’25US$62.11
US$61.68
-0.69%
7.87%US$70.00US$50.00US$68.0819
US$101.86
Fair Value
11.7% undervalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 02:14
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ventas, Inc. is covered by 43 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jacob KilsteinArgus Research Company
Amanda SweitzerBaird
David RodgersBaird